A Focus on MSI-high/ TMB-high Cancers and Biomarkers

Friday, Oct. 13, 2023 | 12-4 p.m. EDT
Hybrid | VIRTUAL AND New York, NY 

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects MSI-high/ TMB-high Cancers and Biomarkers. Free for healthcare professionals, students, patients and patient advocates.

Located in the New York City area? Be sure to join us in-person so you can take advantage of the opportunity to network with the faculty in your area and enjoy a lunch interacting with your peers and experts in the field.

Program Organizers

Andrea Cercek, MD
Memorial Sloan Kettering Cancer Center

Benoit Rousseau, MD, PhD
Memorial Sloan Kettering Cancer Center

Robert Samstein, MD, PhD
Icahn School of Medicine at Mount Sinai Tisch Cancer Institute

Program Agenda

11:00–11:55 a.m.

 

Complimentary Networking Lunch (in-person only)

11:55 a.m.–12 p.m.

 

Welcome

12–12:30 p.m.

   Assessing Biomarkers, MSI, TMB to Make Treatment Decisions 
Timothy A. Chan, MD, PhD – Cleveland Clinic

12:30–1 p.m.

 

Early-stage Disease/Neoadjuvant/Adjuvant, Focus on MSI-high Tumors
Myriam Chalabi, MD –Netherlands Cancer Institute

1–1:30 p.m.

 

Immunotherapy for TMB High Advanced Cancers 
Aurelien Marabelle, MD, PhD – Gustave Roussy

1:30–2 p.m.

 

Immunotherapy for MSI High Advanced Cancers 
Benoit Rousseau, MD, PhD – Memorial Sloan Kettering Cancer Center

2–2:30 p.m.

 

Break

2:30–2:50 p.m.

 

Cancer Immunotherapy in Practice: Toxicities
Thomas Marron, MD, PhD – Mount Sinai Hospital

2:50–3:10 p.m.

 

Cancer Immunotherapy In Practice: Special Patient Populations
James Smithy, MD, MHS – Memorial Sloan Kettering Cancer Center
3:10–4 p.m.   Faculty Case Study Panel

Program Details

Venue Information

The Westin New York at Times Square

270 West 43rd Street, New York, New York, USA, 10036

The Westin New York at Times Square will provide an unforgettable experience in New York City, situated near Times Square, Midtown Manhattan and Madison Square Garden. Walk to Broadway theatres, Central Park and dozens of famed attractions, or enjoy speedy access to all New York City with most subway lines at our hotel's doorstep. After a day of exploration, savor a meal at the vibrant Foundry Kitchen & Bar, serving delicious American cuisine and craft cocktails. Those looking to host a special event in Midtown Manhattan can take advantage of over 34,000 square feet of meeting space, including 13 theaters and three ballrooms, along with bespoke services to ensure a day to remember. Curate your own NYC adventure at The Westin New York at Times Square.

Program Learning ObjectiveS

  • Discuss biomarkers in clinical use with cancer immunotherapies and their relevance to the cancer immunotherapy approaches in use for the treatment of MSI-H/TMB-H cancers.

  • Summarize recent updates in the use of biomarkers for cancer immunotherapies and of cancer immunotherapy for MSI-H/TMB-H cancers including emerging toxicities and management.

  • Implement the use of biomarkers to select appropriate immunotherapy for cancers, including MSI-H/TMB-H cancers.

  • Describe the rationale for the use of cancer immunotherapy in MSI-H/TMB-H cancers.

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

COVID-19 Measures >

At SITC programs, our goal is to have a safe and meaningful in-person experience. SITC will refer to the CDC COVID-19 Community Levels to guide health precautions for in-person meetings. In addition, SITC strongly recommends that in-person meeting attendees take the following precautions: 
•    Stay up to date with COVID-19 vaccinations.
•    Take a rapid COVID test prior to attending a meeting and do not attend in person if you test positive.
•    Do not attend the meeting if you have symptoms that could be consistent with a “cold” or any other respiratory infection and leave the meeting if you develop such symptoms.
•    Wear a mask in crowded indoor settings. 
•   Follow all health and safety protocols as required by SITC and local and state health departments.
•    Review current CDC and applicable local guidance for protecting yourself from COVID-19.
Attendees will have access to the meeting content online if they are unable to attend in person due to illness or a positive COVID test. For hybrid programs, attendees can change from in-person to online-only registration by contacting events@sitcancer.org. 
Registered attendees will be notified in advance of any changes to precautions, recommendations or requirements for a SITC meeting.

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

PACE designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

PACE designates this continuing education activity for 3.5 contact hour(s) (0.35 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.



American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

ABIM_Logo.jpg

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Avoid Fraudulent ACI Registration Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact SITC Staff prior to the live event at (414) 271-2456 or via email education@sitcancer.org.